New addition to the depot 🧬🔬
CRISPR Therapeutics
$CRSP (-2,21 %) is a Swiss biotech company listed on the US stock exchange that was co-founded by CRISPR discoverer Emanuelle Charpentier in 2013.
The joint venture Exa-Cel with Vertex Pharmaceuticals $VRTX (+0,36 %) for the treatment of hereditary blood diseases has already been approved.
But CRISPR Therapeutics also has other irons in the fire.
The cell therapy CTX112 cell therapy is currently in a clinical trial for the treatment of a malignant cancer tumor.
In addition CTX131 in a phase 1 study as a potential treatment for various types of cancer. tested. For cardiovascular diseases, the therapies CTX310 and CTX320 are in the clinical trial phase. In addition, the company is also working with Vertex, for example, on testing the experimental type 1 diabetes therapy CTX212.
Now that the first CRISPR treatment approach has been approved, the first "real" revenues have been generated following several milestone payments. sales.
Analysts estimate these at USD 60.7 million for 2024.
By 2025, this figure should already be USD 333 million (+449%),
then USD 743 million (+123%) in 2026.
However, investment-related losses are still expected.
With a cash position of USD 2.1 billion the company is probably sufficiently liquid to bring treatment approaches to approval.
The share has been under observation for a long time. Due to the high volatility, I will probably keep it in my portfolio for a long time and have to expect periods of heavy losses.
